Here are three things to know:
1. The fiber-based material is bound by a biodegradable polymer.
2. The company will seek additional funding and potential commercialization partners for its orthopedic surgical products.
3. The privately held company aims to eliminate the need for future implantation.
More articles on biologics:
Bone Biologics raises $5.9M: 3 notes
Viscogliosi Brothers to purchase Bioventus’ BMP development program: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
